Rheumatology has arguably benefited like no other field from the proliferation of an increasingly effective pipeline of therapeutics. These medications have dramatically raised the bar for clinical outcomes for our patients in a way that we could not have envisioned a short generation ago. With such therapeutic progress now reaching a widening circle of rheumatic…
It is an exciting time in the world of vasculitis research. More clinical studies and trials are being conducted now than at any time in history. In the past ten years, four drugs have been approved by the U.S. Food & Drug Administration (FDA) and other regulatory agencies specifically for the treatment of vasculitis: Rituximab…
A young man sits down at my COVID-19 immunization station at Maine Medical Center and stares resolutely ahead, focusing on the far wall. He looks nervous. I make sure the needle and syringe are outside his field of vision. That should help. I pick up a Band-Aid from my box of supplies. It’s a Band-Aid…
Recent evidence on how anti-citrullinated protein antibodies, anti-modified protein autoantibodies and rheumatoid factor activity overlap in RA demonstrate new ideas for diagnostics and pathophysiology.
ACR CONVERGENCE 2020—Attention to bone health in people at risk of developing, or who already have, osteoporosis is essential to reduce their increased risk for fragility fractures. Major risk factors for osteoporosis include being female, white, of small frame and having a family history of osteoporosis, as well as having secondary causes of osteoporosis, such…
ACR Convergence panelists discussed how to monitor SSc-ILD patients for ILD severity & the brightening prospects for therapy.
The ACR Review Course featured eight talks providing a practical review of issues encountered by rheumatologists.
New diagnostic approaches combined with new evidence about pathogenesis are providing opportunities to help rheumatologists manage calcium pyrophosphate deposition disease.
In early 2021, Lindsey A. Criswell, MD, MPH, DSc, one of rheumatology’s preeminent autoimmune genetics researchers, will become the new director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases. She will be the first woman to hold that post. Dr. Criswell will be leaving her current position as vice chancellor of research…
Cardiovascular disease (CVD) is a leading cause of death in patients with rheumatoid arthritis (RA). Patients with RA have a 1.5 times increased risk for heart attack compared with the general population. Although the treatment of RA has advanced significantly, the ability to prevent cardiovascular events hasn’t followed. A study in Arthritis Care & Research…